BRCA2 and neoplasm: Accordingly, RP-6685 treatment (oral administration at 80 mg/kg BID for21 days) did not inhibit tumor growth in a BRCA2+/+ HCT116 mouse xenograft but tumor regressionwas observed in the BRCA2–/– HCT116 xenograft during the first 8 days of treatment, althoughit was not sustained throughout the treatment period.